ZAZaid Ali Abdulelah

Zaid Ali Abdulelah

*This is an algorithmically generated author record based on publicly available information.

Zaid Ali Abdulelah has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance of artificial intelligence versus clinician left-ventricular segmentation of cardiac MRI for mortality prediction: a retrospective, multicentre, prognostic study

    by George Joy, Karan Punjabi, George Searle, Zaid A Abdulelah, Tuguldur Gantur, Iain Pierce, George D Thornton, Benjamin Meredith, Hunain Shiwani, Miles Curtis, et al.

  • Open Access

    Echocardiographic Findings in Jordanian Atrial Fibrillation Patients: Analysis from Jo-Fib Study

    by Zaid A. Abdulelah, Kais Al Balbissi, Mohammad Al-Dqour, Ayman Hammoudeh, Ahmed A. Abdulelah

    Background and Objectives: Atrial fibrillation (AF) carries a huge socioeconomic burden as it is the most encountered cardiac arrhythmia with a significant morbidity. Echocardiographic (Echo) imaging is of monumental value in providing insight into assessing the cardiac function and anatomy, etiology, and risk stratification of AF patients, which will ultimately lead to the best management plan. Materials and Methods: A total of 2160 adult patients diagnosed with AF in 18 hospitals and 30 out-patient cardiology clinics in Jordan and 1 hospital in the Palestinian Territories were enrolled in this study from May 2019 to January 2021. Ultimately, 1776 patients were included in the analysis after going through the exclusion criteria. Results: The majority of our participants were found to have normal EF at the time of enrollment, with only 31.6% exhibiting a decreased EF. Only 40% of overall patients had Echo evidence of left ventricular hypertrophy (LVH). These patients were older (70.27 ± 10.1 vs. 66.0 ± 14.3, p < 0.001), more obese (45.2% vs. 37.3%, p-value < 0.001), and had a more frequent occurrence of HTN (89.0% vs. 65.6%, p < 0.001) and DM (49.2% vs. 40.1%, p < 0.001) when compared to patients without LVH. A proportion of 84.2% of female patients had abnormal left atrial (LA) size (>3.8 cm), in contrast to only 53.4% of males (LA > 4.2 cm). Pulmonary hypertension (PH) was only observed in 27.9% of our patients, and when comparing patients with PH vs. patients without PH, decreased EF (p = 0.001), a higher prevalence of OSA (6.7% vs. 3.8%, p = 0.009), female predominance (60.3% vs. 39.7%, p < 0.001), and older age (70.2 ± 10.7 vs. 66.7 ± 13.6, p < 0.001) were observed in patients with PH. Conclusion: This study provides the first reported insights on the atrial fibrillation-related echocardiographic findings in a Middle Eastern population. Notably, our study demonstrates that the majority of the studied population have no evidence of LVH and have preserved EF on baseline. However, LA enlargement was extremely frequent among females but not in males, warranting further evaluation to determine the factors contributing to such a difference.


  • Open Access

    The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review

    by Khaled S. Al Oweidat, Ahmed A. Abdulelah, Ahmad A. Toubasi, Mohammad Abdulelah, Nour Z. Alatteili, Zaid A. Abdulelah

    Systemic sclerosis (SSc) is predominantly characterized by an array of cutaneous manifestations including Raynaud’s phenomenon, calcinosis, telangiectasias, and skin fibrosis contributing toward substantial morbidity and diminished quality of life. The monumental impact of the disease regarding mortality is due to its pulmonary involvement known as SSc‐associated interstitial lung disease (SSc–ILD). Currently, treatment is chiefly directed toward impeding disease progression with the mainstay treatment approaches involving the utilization of cyclophosphamide, mycophenolate mofetil, rituximab, and tocilizumab. Recently, a tyrosine kinase inhibitor, nintedanib, has been approved for the treatment of SSc–ILD and thus became the first medication to be fully licensed for SSc–ILD. A systematic review based on the Preferred Reporting Items of Systematic Review with Meta‐analysis (PRISMA) was conducted after successful registration in PROSPERO to evaluate the efficacy and safety of nintedanib in SSc–ILD. We searched PubMed, Scopus, and CENTRAL up to the first of September 2023 utilizing the following keywords: ((Diffuse Parenchymal Lung Disease) OR (Diffuse Parenchymal Lung Diseases) OR (Interstitial Lung Disease) OR (Interstitial Lung Diseases) OR (Interstitial Pneumonia) OR (Interstitial Pneumonitis) OR (Pulmonary Fibrosis)) AND ((Systemic Scleroderma) OR (Systemic Scleroderma)) AND ((BIBF 1120) OR (BIBF‐1120) OR (BIBF1120) OR (Nintedanib esylate) OR (Ofev) OR (Vargatef)). The clinical safety profile of nintedanib was deemed more favorable than other therapeutic regimens currently utilized, in addition to adequate clinical efficacy toward SSc–ILD.


  • Analysis of terminated pulmonary hypertension clinical trials. What are we doing wrong?

    by Mohammad Abdulelah, Zaid A. Abdulelah, Muayad Azzam, Ruba Ghalayni, Hassan Kawtharany, Farah Khraisat, Hussein Abdulelah, Lina AlQirem, Ahmed A. Abdulelah


  • Open Access

    Fibrous Pericardial Mass Signifying the Importance of Advanced Cardiovascular Imaging: A Case Report

    by Zaid Abdulelah, Ahmed Abdulelah, Abdulqader Alsayed Issa, Kais Al Balbissi

    Background: Pericardial masses are an extremely rare group of diseases which can be classified based on etiology. The presentation of pericardial masses varies considerably from one individual to another, ranging from an asymptomatic presentation with an incidental finding on imaging, to presenting with non-specific signs and symptoms. Due to the enigmatic nature and presentation of pericardial masses, diagnostic imaging is mandatory. Case Presentation: A 69-year-old patient presented to our cardiology clinic complaining of intermittent shortness of breath upon moderate exertion in the absence of chest pain, paroxysmal nocturnal dyspnea, orthopnea, dizziness, palpitations, or lower limb edema. The patient’s past medical history was significant because of his history of pericarditis associated with pericardial effusion 6 years prior to presentation at our clinic. Despite adequate medical treatment, the patient complained of a relapsing and remitting pattern of symptoms that mandated the performance of advanced cardiovascular imaging, namely, cardiac magnetic resonance imaging, which revealed the presence of a profound pericardial mass. Conclusion: Despite the fact that relapsing pericarditis is a well-established complication following acute pericarditis, the presentation of a complication such as a fibrous pericardial mass evident on cardiac MRI has essentially been unreported in the literature previously.

  • Predictors of outcome in patients with moderate mixed aortic valve disease

    by Kush P Patel, Michael McKenna, George D Thornton, Sebastian Vandermolen, Zaid Ali Abdulelah, Wael Awad, Andreas Baumbach, Anthony Mathur, Thomas A Treibel, Guy Lloyd, et al.

    Objectives: Grading the severity of moderate mixed aortic stenosis and regurgitation (MAVD) is challenging and the disease poorly understood. Identifying markers of haemodynamic severity will improve risk stratification and potentially guide timely treatment. This study aims to identify prognostic haemodynamic markers in patients with moderate MAVD.Methods: Moderate MAVD was defined as coexisting moderate aortic stenosis (aortic valve area (AVA) 1.0–1.5 cm2) and moderate aortic regurgitation (vena contracta (VC) 0.3–0.6 cm). Consecutive patients diagnosed between 2015 and 2019 were included from a multicentre registry. The primary composite outcome of death or heart failure hospitalisation was evaluated among these patients. Demographics, comorbidities, echocardiography and treatment data were assessed for their prognostic significance.Results: 207 patients with moderate MAVD were included, aged 78 (66–84) years, 56% male sex, AVA 1.2 (1.1–1.4) cm2and VC 0.4 (0.4–0.5) cm. Over a follow-up of 3.5 (2.5–4.7) years, the composite outcome was met in 89 patients (43%). Univariable associations with the primary outcome included older age, previous myocardial infarction, previous cerebrovascular event, atrial fibrillation, New York Heart Association >2, worse renal function, tricuspid regurgitation ≥2 and mitral regurgitation ≥2. Markers of biventricular systolic function, cardiac remodelling and transaortic valve haemodynamics demonstrated an inverse association with the primary composite outcome. In multivariable analysis, peak aortic jet velocity (Vmax) was independently and inversely associated with the composite outcome (HR: 0.63, 95% CI 0.43 to 0.93; p=0.021) in an adjusted model along with age (HR: 1.05, 95% CI 1.03 to 1.08; p<0.001), creatinine (HR: 1.002, 95% CI 1.001 to 1.003; p=0.005), previous cerebrovascular event (85% vs 42%; HR: 3.04, 95% CI 1.54 to 5.99; p=0.001) and left ventricular ejection fraction (LVEF) (HR: 0.97, 95% CI 0.95 to 0.99; p=0.007). Patients with Vmax ≤2.8 m/s and LVEF ≤50% (n=27) had the worst outcome compared with the rest of the population (72% vs 41%; HR: 3.87, 95% CI 2.20 to 6.80; p<0.001).Conclusions: Patients with truly moderate MAVD have a high incidence of death and heart failure hospitalisation (43% at 3.5 (2.5–4.7) years). Within this group, a high-risk group characterised by disproportionately low aortic Vmax (≤2.8 m/s) and adverse remodelling (LVEF ≤50%) have the worst outcomes.


  • A 66-year-old man with abnormal thyroid function tests

    by Yazan N. Alhalaseh, Zaid A. Abdulelah, Ahmad O. Armouti, Ayman A. Zayed

    Release date: October 1, 2019Expiration date: September 30, 2020Estimated time of completion: 1 hourClick here to start this CME/MOC activity.